Novartis "buy"

11.09.06 - Jyske Bank

LONDON, September 11 (newratings.com) - Analysts at Jyske Bank maintain their "buy" rating on Novartis (NOVN). The target price is set to CHF85.

In a research note published this morning, the analysts mention that the company is expected to continue to witness sustained development in its pharmaceutical business on account of the sales for key products. Novartis is expected to launch new products in the near future, Jyske Bank adds.